Online Fiabetes Print ISSN American Alpa-lipoic Association: Economic costs of diabetes in the US in Alpha-lipoic acid and diabetes 50 — Alpha-lipoic acid and diabetes Diabets, Federici Cancer prevention tips, Rusciano D, Evangelista M, Pescosolido N: Oxidative stress in preretinopathic diabetes subjects and antioxidants. While these three systematic reviews offer some promising evidence, the study methods varied greatly among the individual studies. Currently, mitochondria dysfunction, oxidative stress and inflammation play a key role in the pathogenesis of NAFLD and NASH [ 55 ].

Video

Why Alpha-Lipoic Acid Is A Must For Diabetics - And A Great Daily Supplement For Everyone

Alpha-lipoic acid and diabetes -

Thus, patients entered the run-in phase. Among these, six patients were not randomly assigned because of unstable TSS or withdrawal of consent. Most patients 12 discontinued because of adverse events: 1 in the placebo group, 0 in the ALA group, 5 in ALA, and 6 in ALA One patient in the ALA group did not complete the trial because of lack of efficacy; another one patient each in the ALAand ALA group discontinued for other reasons.

The clinical characteristics of the patients are shown in Table 1. There were also no significant differences among the groups in the mean baseline TSS and its individual subscores. No significant differences among the three ALA groups and the placebo group were noted for paresthesia and numbness.

The mean TSS levels during the placebo run-in and the randomized double-blind period of the trial are illustrated in Fig. No significant differences were observed among the three ALA groups for the changes in mean TSS at any of the time points examined.

The mean levels of the NSC scores, NIS, and NIS [LL] at screening and their changes after 5 weeks of treatment are given in Table 3. There were no significant differences among the groups at screening. No significant differences among the groups were noted for any of the nerve conduction studies data not shown.

The results of the SYDNEY 2 trial demonstrate that oral treatment with ALA over 5 weeks improved the positive sensory symptoms scored by the TSS in diabetic patients with DSP.

This overall effect was not dose dependent, as there were no differences in the changes in mean TSS among all active groups. A significant improvement in TSS was noted as soon as after 1 week with ALA and after 2 weeks with ALA and ALA Among the individual TSS symptoms, improvement in pain but not paresthesia and numbness was observed.

Moreover, ALA ameliorated the NSC and neuropathy impairment scores NIS and NIS [LL]. The mechanisms of the rapid improvement in both neuropathic symptoms and deficits may be related to an improvement in nerve blood flow mediated by the antioxidant action of ALA 19 — This effect was accompanied by reductions in plasma levels of interleukin-6 and plasminogen activator-1, suggesting that the drug may improve endothelial dysfunction via anti-inflammatory and antithrombotic mechanisms Intravenous infusion of mg ALA exerts an acute effect on microcirculation in patients with diabetic polyneuropathy 28 , The impairment of nitric oxide—mediated vasodilation in diabetes has been attributed to increased vascular oxidative stress.

At this point, acute infusion of ALA improved nitric oxide—mediated endothelium-dependent vasodilation in diabetic patients The safety analysis revealed an overall favorable safety profile for the low dose.

The most frequent adverse event was a dose-dependent increase in the incidence of nausea. and 1, mg q. The rate of adverse events with 1, mg q. intravenously However, a direct comparison of these studies is not possible because of the different routes of administration and oral drug formulations used.

The oral HR high release formulation of ALA used in this study was specifically developed to reduce the relatively high variability in drug plasma levels after oral administration of the conventional formulation.

Hermann, unpublished observations. The number needed to treat for the mg dose of oral ALA q. Whether the observed favorable short-term effect of ALA on neuropathic symptoms and deficits can be translated into slowing the progression of diabetic polyneuropathy in the long term is unknown.

However, our finding that neuropathic deficits such as impaired sensory function were improved is encouraging, because these are major risk factors in the development of neuropathic foot ulcers It is notable that this improvement is clinically meaningful and demonstrable within 1—2 weeks. In the absence of a dose response and because the higher doses resulted in increased rates of gastrointestinal side effects, mg once daily seems to be the most appropriate oral dose.

Mean TSS levels on a weekly basis during the placebo run-in and the randomized double-blind period of the trial. Baseline levels and changes from baseline negative values correspond to improvement in the TSS and its individual subscores after 5 weeks of treatment last value carried forward.

Screening levels and changes from screening in NSC scores, NIS, and NIS [LL] after 5 weeks of treatment last value carried forward. This study was supported by MEDA Pharma, Bad Homburg, Germany.

In addition to the authors listed, the following colleagues contributed equally to the study: Natalia Chernikova, MD; Barbara Ellers-Lenz, Dipl. oec; Igor Strokov, MD; Julio Wainstein, MD; and Hans J.

Tritschler, PhD. received honoraria for speaking activities and research grants from MEDA. A table elsewhere in this issue shows conventional and Système International SI units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. C Section solely to indicate this fact. Sign In or Create an Account.

Search Dropdown Menu. header search search input Search input auto suggest. filter your search All Content All Journals Diabetes Care. Advanced Search.

User Tools Dropdown. Sign In. Skip Nav Destination Close navigation menu Article navigation. Volume 29, Issue Previous Article Next Article. RESEARCH DESIGN AND METHODS—. Experts think antioxidants protect against cell damage. ALA helps fight free radicals, which are the substances that cause cell damage.

ALA may also help the body be more sensitive to insulin. People with diabetes might use ALA in supplemental form to help neuropathy. This supplement is promising, but you should still address risks and certain questions before you take ALA.

Neuropathy can develop in people with diabetes as a result of high blood glucose, or hyperglycemia. People with diabetes are at a high risk of nerve damage when blood glucose levels are poorly controlled over many years.

Your symptoms may vary depending on the type of neuropathy you have and which nerves are affected. Diabetes can lead to several different types of neuropathy, each with different symptoms. ALA may help ease the symptoms of peripheral and autonomic neuropathy.

The symptoms of nerve damage in people with diabetes most commonly occur in the feet and legs, but they can also occur in the hands and arms. Peripheral neuropathy can cause pain in these areas. It can also cause:.

Diabetes can also affect the nerves in your autonomic nervous system. Your autonomic nervous system controls your. Early research on ALA suggests it may help treat blood pressure or heart problems associated with autonomic neuropathy.

Further study is needed to confirm this finding. This antioxidant is both water- and fat-soluble. All areas of your body may absorb it.

ALA is a potential natural method for relieving nerve pain that occurs due to diabetes. ALA potentially lowers blood glucose, which can protect from nerve damage.

ALA is available in different forms for people with diabetes. Some studies have involved the use of intravenous IV versions of ALA. A healthcare professional helps administer IV ALA. Excessively high doses of IV ALA can harm your liver.

Some doctors may use it in shots. ALA is also available in oral supplements. Your vision can be distorted if your macula thickens due to fluid buildup. Philadelphia, PA: Elsevier; Mitkov MD, Aleksandrova IY, Orbetzova MM.

Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med Plovdiv. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy.

Diabetes Care. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-linoic acis.

Free Radic Biol Med. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant.

Free Rad Bio Med. Panigrahi M, Sadguna Y, Shivakumar BR, et al. Alpha-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res. Segermann J, Hotze A, Ulrich H, et al. Effect of alpha-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels.

Tatar A, Korkmaz M, Yayla M, et al. Anti-inflammatory and anti-oxidative effects of alpha-lipoic acid in experimentally induced acute otitis media.

J Laryngol Otol. Xu J, Gao H, Song L, et al. Flaxseed oil and alpha-lipoic acid combination ameliorates hepatic oxidative stress and lipid accumulation in comparison to lard. Lipids Health Dis. Yoo TH, Lee JH, Chun HS, Chi SG.

a-Lipoic acid prevents p53 degradation in colon cancer cells by blocking NF-kB induction of RPS6KA4. Anticancer Drugs. Ziegler D, Ametov A, Barinov A, et al.

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy.

Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes.

Share Facebook Twitter Linkedin Email Home Health Library. Alpha-lipoic acid Dihydrolipoic acid; Lipoic acid; Lipolate; Thiotic acid.

Dietary Sources If you are healthy, your body makes enough alpha-lipoic acid. Available Forms Alpha-lipoic acid supplements are available as capsules. How to Take It Pediatric Alpha-lipoic acid has not been studied in children, so it is not recommended for pediatric use.

Adult Check with your doctor regarding dosing recommendations. Precautions Because of the potential for side effects and interactions with medications, you should take dietary supplements only under the supervision of a health care provider.

Side effects are generally rare and may include insomnia, fatigue, diarrhea, and skin rash. Possible Interactions If you are being treated with any of the following medications, you should not use alpha-lipoic acid without first talking to your health care provider.

Medications for diabetes Apha-lipoic acid can combine with these drugs to lower blood sugar levels, raising the risk of hypoglycemia or low blood sugar. Chemotherapy medications Alpha-lipoic acid may interfere with some chemotherapy medications.

Coronavirus COVID Alphw-lipoic Latest Stay hydrated for peak performance Visitation Policies Visitation Policies Visitation Policies Visitation Alpha-lipoic acid and diabetes Visitation Policies COVID Testing Vaccine Information Vaccine Alphx-lipoic Vaccine Information. Alpha lipoic acid ALA is an antioxidant. It is quickly absorbed from the gastrointestinal tract. It dissolves in both water and fat in the body. ALA is frequently used to treat diabetic neuropathy. This is a sensory change that includes stinging, burning, pain, and numbness in parts of the skin.